Atria Investments Inc Has $217,000 Holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Atria Investments Inc raised its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 20.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,585 shares of the medical technology company’s stock after buying an additional 3,976 shares during the period. Atria Investments Inc’s holdings in Alphatec were worth $217,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in ATEC. State Street Corp raised its stake in Alphatec by 10.1% in the 3rd quarter. State Street Corp now owns 3,138,960 shares of the medical technology company’s stock valued at $17,453,000 after acquiring an additional 287,350 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Alphatec by 11.3% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock valued at $16,280,000 after purchasing an additional 297,850 shares during the last quarter. New York State Common Retirement Fund raised its position in shares of Alphatec by 21.2% in the fourth quarter. New York State Common Retirement Fund now owns 1,202,334 shares of the medical technology company’s stock valued at $11,037,000 after purchasing an additional 210,519 shares during the period. Walleye Capital LLC lifted its stake in shares of Alphatec by 3.2% during the 3rd quarter. Walleye Capital LLC now owns 1,061,462 shares of the medical technology company’s stock worth $5,902,000 after buying an additional 32,529 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Alphatec by 2.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 846,224 shares of the medical technology company’s stock worth $7,768,000 after buying an additional 23,002 shares during the period. 66.35% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have weighed in on ATEC shares. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price target on shares of Alphatec in a report on Thursday, February 27th. Barclays increased their target price on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 22nd. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research note on Tuesday, January 14th. StockNews.com raised Alphatec from a “sell” rating to a “hold” rating in a report on Friday, February 28th. Finally, Piper Sandler lifted their target price on Alphatec from $12.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $17.67.

Insider Activity at Alphatec

In other news, EVP David Sponsel sold 33,732 shares of the firm’s stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $10.83, for a total value of $365,317.56. Following the sale, the executive vice president now directly owns 668,977 shares in the company, valued at approximately $7,245,020.91. This trade represents a 4.80 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Patrick Miles sold 6,687 shares of Alphatec stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $12.00, for a total transaction of $80,244.00. Following the sale, the chief executive officer now directly owns 5,501,715 shares in the company, valued at $66,020,580. This trade represents a 0.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 337,321 shares of company stock valued at $3,828,060 over the last three months. 22.80% of the stock is owned by insiders.

Alphatec Stock Performance

ATEC opened at $9.34 on Wednesday. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $14.88. The firm has a market cap of $1.35 billion, a P/E ratio of -7.30 and a beta of 1.39. The business’s fifty day moving average is $10.95 and its 200-day moving average is $8.80.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). The firm had revenue of $176.79 million for the quarter, compared to analyst estimates of $172.74 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. Sell-side analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.